# Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04569435** · PHASE2 · COMPLETED · sponsor: **Annexon, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ANX005

## Key facts

- **NCT ID:** NCT04569435
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-15
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-04-23
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569435, "Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04569435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*